- Global Locations -


Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705


Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531


Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates


Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Excessive Daytime Sleepiness Market Snapshot (2023 to 2033)

In the year 2022, the worldwide excessive daytime sleepiness market was estimated to be worth US$4.9 billion. This market is predicted to generate US$ 5.33 billion by 2023 and US$ 12.39 billion by 2033, with a fast-expanding CAGR of 8.8% from 2023 to 2033.

The percentage of complaints about sleeping disorders has significantly increased after the COVID-19 epidemic. The types of sleep disorders were intrinsic (originating from the body), extrinsic (caused by external factors), and circadian rhythm disruptions. People's psychological stress levels have grown as a result of the COVID-19 lockdown's social isolation and disruption of daily routines, which has led to an increase in sleep problems globally.

According to a February 2021 paper published in the Journal of Clinical Sleep Medicine, around 40% of the general public and the healthcare industries have reported various sleep issues during the COVID-19 pandemic. One of the main factors driving the market for excessive daytime sleepiness is extreme tiredness due to different nighttime routines. As a result, there is a rising need for treatments for excessive daytime drowsiness to stop the spread of the sleep disorders brought on by COVID-19.

The market is expected to rise as a result of the increased detection of cases of excessive daytime sleepiness. The National Center on Sleep Disorders Research is one institution that has pushed for the need to address the issue. In an article published in April 2020 by Cigna Health and Life Insurance Company (CHLIC), it was noted that from February 16 to March 15 of this year, prescription sales for sleep disorders climbed by 14.8% compared to the same time in 2019. Throughout the course of the forecast timeframe, the market is anticipated to grow significantly due to the spike in the development of pipeline pharmaceuticals and the rise in lifestyle disorders, particularly anxiety, and depression. Nonetheless, adverse effects from medications for sleep disorders are predicted.

The excessive daytime sleepiness therapy market is anticipated to be dominated by the stimulants segment. The market for treating excessive daytime drowsiness is anticipated to grow as a result of significant advancements in the field and the approval of innovative medications. The most popular form of therapy for excessive daytime drowsiness is stimulants. According to a January 2020 article in CNS Meds, stimulants that were used to address excessive daytime sleepiness are intended to increase alertness and address the signs of sleep paralysis and disrupted nocturnal sleep. Modafinil is among the most often prescribed stimulants for the therapy of narcolepsy. A central nervous system (CNS) stimulant without amphetamines that promotes wakefulness is known as modafinil. The most thoroughly researched stimulant, modafinil, was found to have an adequate safety profile and a considerable recovery in excessive daytime drowsiness.

Some of the recent developments that took place in the global market for excessive daytime sleepiness are:

  • NLS Pharma Ltd. announced in July 2022 that the European Medicines Agency (EMA) along with Committee for Orphan Medical Products (COMP) has given a favorable opinion to authorize Mazindol ER (Quilience) Orphan Drug Designation (ODD) for the management of daytime sleepiness.
  • The INTUNE research, a Phase 3 trial examining the effectiveness and safety of pitolisant among adult individuals suffering from idiopathic hypersomnia (IH), was started in April 2022 by Harmony Biosciences Holdings, Inc.

Data Point

Key Statistics

Expected Market value in 2023

US$ 5.33 Billion

Expected Market value in 2033

US$ 12.39 Billion

Growth Rate (2023 to 2033)


Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Surging Cases of Excessive daytime sleepiness, Advancing Healthcare and Research to rocket the Excessive daytime sleepiness Market

Excessive daytime sleepiness or Hypersomnia is a sleep disorder of persistent sleep during the daytime. Excessive daytime sleepiness is caused by sleep deprivations due to obstructive sleep apnea (OSA), Narcolepsy, other sleep-altering/depriving habits, and medical or psychiatric conditions. 

Narcolepsy is a neurological condition of long-term reduced regulation of the sleep-wake cycle and OSA is caused by airway blockages. According to the National Sleep Foundation, 40% of the global population is coping with Excessive Daytime Sleepiness.  Excessive daytime sleepiness is diagnosed with daytime excessive sleepiness, low energy, and frustration. Therapeutic Drugs include stimulants, anti-depressants, Amphetamine salts, and Sodium oxybate.

Devices such as continuous positive airway pressure (CPAP) machines are used for Excessive daytime sleepiness therapies and Nocturnal polysomnography, polysomnography, and other devices are used for Excessive daytime sleepiness diagnostics.

Coronavirus and lockdown have propelled the global excessive daytime sleepiness market the economic crisis, work-from-home stress, and disrupted circadian cycle have surged the excessive daytime sleepiness market.

The devices for OSA, including CPAP, BiPAP devices, and special ventilators were deliberated with massive production to meet the unprecedented demands of increasing Coronavirus patients. The overall global market of Excessive daytime sleepiness market is growing at a lucrative rate.

Excessive Daytime Sleepiness Market: Drivers and Restraints

The drivers of the global excessive daytime sleepiness market include the increase in population, awareness, healthcare expenditure diverse drug array, and Government reimbursement policies. The advancing R&D and technology of manufacturers and academics rocket the excessive daytime sleepiness market by developing novel therapeutics and unraveling the pathogenesis.

Several targeted drugs and devices for Excessive daytime sleepiness diagnosis and therapies are in pipelines and clinical trials to hit the market. However, the global excessive daytime sleepiness market is constrained by stringent drug regulations of the government, lack of acceptance of OSA masks and wearables because of their discomfort, and higher cost. 

Although advancing technologies are propelling the global excessive daytime sleepiness market and opening the vast horizon of opportunities for future growth, coupled with the emerging telemedicine technology and mobile health with improved convenience of treatment with the facility of video visiting sleep doctors. 

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Excessive Daytime Sleepiness Market: Overview

The global Excessive daytime sleepiness market is expected to a growth revamp driven by the increasing Excessive daytime sleepiness disorders, therapy demands, and advancing R&D. By Diseases, OSA dominates the market of excessive daytime sleepiness market with its giant market of devices and drugs.

The segment of Narcolepsy is expanding at a faster pace. By treatment, devices for excessive daytime sleepiness market rules the segment with its diverse and massive market of masks, wearable sleep trackers, cushions, Positive Airway Pressure Devices, CPAPs, and others.

The segment of Therapeutic drugs is growing at a faster pace than the sodium oxybate market. By Distribution channels, Hospitals, and sleep centers occupy the largest segment of the excessive daytime sleepiness market, propelled by advanced diagnostics, precision therapies, and government reimbursements. The Home Care Settings segment is growing at a faster rate with affordability and comfort.

Excessive Daytime Sleepiness Market: Regional Outlook

North America dominates the global excessive daytime sleepiness market with rising patients, key players, advanced healthcare, and research. Europe holds the second-largest excessive daytime sleepiness market due to its high prevalence of excessive daytime sleepiness and advanced healthcare.

The Asia-Pacific excessive daytime sleepiness market is revamping with the highest growth rate, driven by its rising Excessive daytime sleepiness cases, advancing therapies, and technology. South Asian regions including India, where Government and healthcare institutions provide aid for awareness and therapies for excessive daytime sleepiness.

Latin America's excessive daytime sleepiness market is also growing with the surging cases of OSA and improving healthcare. The Middle East & Africa excessive daytime sleepiness market is also elevating due to the surging cases of OSA, narcolepsy, and an increase in awareness.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Excessive Daytime Sleepiness Market: Key Players

The key players in the global excessive daytime sleepiness market include

  • Teva Pharmaceutical Industries Ltd.
  • GE Healthcare 
  • Jazz Pharmaceuticals 
  • Compumedics
  • Fisher & Paykel Healthcare
  • BMC Medical Co. Ltd.
  • Avadel Pharmaceuticals plc 
  • Cadwell Laboratories Inc. Ltd 
  • GlaxoSmithKline plc 
  • Braebon Medical Corporation 
  • Pfizer 
  • Becton Dickinson
  • Theranexus 
  • LivaNova PLC and Merck & Co.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.

The research report provides analysis and information according to market segments such as geographies, applications, and industries.

The report covers exhaust analysis on

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Indication
  • Value Chain

Regional analysis includes

  • North America (USA, Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, United Kingdom, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

Excessive daytime sleepiness Market: Segmentation

The global excessive daytime sleepiness market is segmented into diseases, treatment, distribution channels, and regions.


  • Obstructive Sleep Apnea (OSA)
  • Narcolepsy


  • Devices (Diagnostics, Therapy)
  • Therapeutic Drugs (Stimulants, Anti-Depressants, Amphetamine salts, Sodium oxybate)

Distribution channels:

  • Hospitals & Sleep Laboratories
  • Home Care Settings

Explore Healthcare Insights

View Reports

Excessive Daytime Sleepiness Market

Schedule a Call